Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients

Hatice Kilic*, Emine Arguder1, Aysegul Karalezli1, Ebru Unsal1, Rahmet Guner2, Bircan Kayaslan2, Imran Hasanoglu3, Ihsan Ates4, Musa Civak5, Esmehan Akpinar5, Ebru Parlak5, Filiz Sadi5, Yasin Kocaman5, Sibel Gunay5, Esra Metan5, Mukremen Er6, Aynil Dalkiran6, Habibe Hezer5, Hulya Erguden6, Zeynep Hancigo glu5, Ayse Kalem2, Fatma Eser2, Adalet Aypak6, Esragul Akinci6, Selma Karahmetoglu4, Emin Gemcioglu4, Emra Kalkan4, Osman Inan4, Abdulrezzak Yilmaz4, Bagdagul Guler4, Esra Copuroglu4, Isil Turan7, Derya Gokmen8, Serhat Hayme8 and Aziz Ahmet Surlu9

1Department of Pulmonary Medicine, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey. 2Department of Infectious Disease, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey. 3Department of Internal Medicine Disease, Faculty of Medicine, Ankara University of Health Science, Ankara City Hospital, Ankara, Turkey. 4Department of Internal Medicine Diseases, Ankara City Hospital, Ankara, Turkey. 5Department of Chest Diseases, Ankara City Hospital, Ankara, Turkey. 6Department of Infectious Disease, Faculty of Medicine, University of Health Science, Ankara, Turkey. 7Department of Anesthesia, Ankara City Hospital, Ankara, Turkey. 8Department of Biostatistics, School of Medicine, Ankara University, Ankara, Turkey. 9Department of General Surgery, Ankara City Hospital, Ankara, Turkey

Background: The aim of the study is to assess the effect of chronic lung disease on mortality in patients hospitalized with the diagnosis of prevariant COVID-19 Pneumonia compared to patients without chronic lung disease.

Research design and methods: A cohort of 1,549 patients admitted to the pandemic clinic with a COVID-19 Pneumonia diagnosis was analyzed. Group 1 and Group 2 were compared in terms of the treatment they received, admission to intensive care, mortality and follow-up parameters.

Results: The patient group with COVID-19 and lung disease consisted of 231 participants (14.91%) (Group 1). The patient group with COVID-19 but without lung disease had 1,318 participants (85.19%). Group 1 cases were found to receive more oxygen therapy and mechanical ventilation than Group 2 cases (p ≤ 0.001). Following univariate and multiple logistic regression analyses, it was determined that patients with chronic lung disease had a 25.76% higher mortality risk [OR: 25.763, 95% CI (Lower-Upper) (2.445–271.465), p = 0.007].
Conclusion: It was found that chronic lung disease contributed significantly to mortality in this study. Among chronic lung diseases, Chronic Obstructive Pulmonary Disease (COPD), lung cancer and interstitial lung diseases (ILDs) were shown to be more effective than other chronic lung diseases in patients with prevariant COVID-19 population.

KEYWORDS
COVID-19, lung, chronic, mortality, COPD, lung cancer, interstitial lung disease

Introduction

COVID-19 has had tremendous negative effects worldwide. According to a WHO report dated 2 May 2020, 3,267,184 cases had been diagnosed with COVID-19 and 229,971 deaths (7.03% fatality rate) had occurred (1, 2). The United States (US) became the epidemic center of this pandemic, reporting an estimated 956,000 cases of COVID-19 infections, and the largest concentration was in New York City and its surrounding areas (approximately 35% of all the US infections) (3, 4). According to the Health Ministry Data of Turkey, however, the total number of cases was 124,375 in Turkey, and there were 3,336 deaths (case fatality rate 2.68%) as of 2 May, 2020 (1).

With such alarming consequences in its short history, the infection has the common symptoms of respiratory symptoms, fever, cough, and dyspnea. Also, pneumonia, severe acute respiratory infection, kidney failure, and even death may develop in more serious cases.

According to the WHO’s COVID-19 report of the People’s Republic of China, death cases were generally individuals with advanced age or concomitant systemic disease (hypertension, diabetes, cardiovascular disease, cancer, chronic lung diseases, and other immunosuppressive conditions) (1).

It is stated that chronic diseases accompanying the course of COVID-19 pandemic affect the severity and prognosis of the disease. However, there are only a few publications on the effect of comorbid lung diseases.

In light of these findings, this study was intended to investigate patients with chronic lung diseases and their effects on disease severity, intensive care hospitalization and mortality in patients hospitalized in our hospital.

Materials and methods

This is a retrospective and observational study covering patients admitted to the Pandemic Clinic between March 11, 2020 and May 31, 2020 (patients with pulmonary diseases, infectious diseases, and those who applied to internal medicine clinics) with a COVID-19 Pneumonia diagnosis at the hospital.

The plan of the study was to record the study parameters of cases from patients’ files in the hospital system, save them as excel data, and conduct statistical analysis. The study was devised to include 1,549 patients. COVID-19 cases aged over 18 were accepted in our study.

Cases with the diagnosis of asthma and chronic obstructive lung disease (COPD) who were followed by internal and pulmonary medicine clinics under the inhaler treatment were recorded. Cases having diagnosis of interstitial lung disease (ILD) before the diagnosis of COVID-19 Pneumonia were defined as ILD group. Cases who were receiving a treatment for the diagnosis of lung cancer and were being followed. The diagnoses of all the cases were recorded, depending on the files and records in the hospital information system. The cases with asthma, COPD, ILD and lung cancer were grouped as the chronic lung diseases patients.

According to the case definitions suggested by the Turkish Ministry of Health Science Board, patients with possible and definitive cases were included. Patients with positive Real-Time Polymerase Chain Reaction (PCR) tests and patients diagnosed with Clinical/radiological COVID-19 were evaluated together (1).

Demographic features of the patients with chronic lung disease (Group 1) and without chronic lung disease (Group 2) were compared in terms of the treatment they receive, admission to intensive care, mortality and follow-up parameters such as age, gender, duration of symptoms, additional diseases, smoking status, presence of asthma and Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, presence of ILD, presence of lung cancer, PCR test results, number of performed PCR tests, severity of the disease in the demographic data (serious or moderate and mild disease), follow-up place (inpatient, intensive care), whether intubation was required or not and the treatments used (Plaquenil, Kaletra, Favipiravir, Tocilizumab, Azithromycin, Oseltamivir, other antibiotic treatments). Hospitalization period, hospitalization time in intensive care unit, routine blood tests (C-reactive Protein, Hemogram, Biochemistry, D-Dimer, Ferritin, Interleukin-6, Fibrinogen, Serum Iron Levels) and hospital information system records were evaluated and analyzed.
Statistical analysis

All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) for Windows version 15.0 (SPSS, Chicago, IL, USA). Shapiro–Wilk and Kolmogorov–Smirnov tests were used to assess the assumption of normality. Normally distributed continuous variables were expressed as mean ± standard deviation while the continuous variables that did not have a normal distribution were expressed as median (minimum–maximum). Also, categorical variables were summarized as counts (percentages). Comparisons of continuous variables between two independent groups were performed using Student’s t-test and Mann–Whitney U-test. Associations between categorical variables were determined by Chi-square test and Fisher’s Exact test. In order to define the risk factors of mortality, risk ratios (RR) were estimated by negative binomial regression model with robust error variances. A two-sided p-value < 0.05 was considered to be statistically significant.

Results

COVID-19 patients with lung disease (group 1) and those without (group 2) were compared in terms of demographic parameters. Among the comorbidities, diabetes mellitus, coronary artery disease and hypertension were observed with a higher frequency in patients with chronic lung disease than in those without (p = 0.001) (Table 1). Symptom of dyspnea was higher in group 1 than group 2, and oxygen saturation levels were lower in group 1 (p = 0.001). Groups were compared in terms of pneumonia severity, intensive care admission and mortality. Group 1 cases were found to receive more oxygen therapy and mechanical ventilation than group 2 cases (Table 2). It was also found that mortality rates were higher than group 2. Groups were compared in terms of laboratory parameters (Table 3).

Subgroup analysis was performed in terms of chronic lung diseases. There was no significant difference between patients with and without asthma in terms of severity of pneumonia, admission to intensive care unit and mortality. Patients with and without COPD were compared end critical illness, pharmacotherapy, oxygen therapy, and mortality were found to be significantly higher in patients with COPD than those without (p ≤ 0.001). There was no significant difference between the groups with and without ILD. There was only a significant difference in mortality between patients with and without ILD [n %, 2 (18.2), 39 (2.5), p = 0.03)]. Patients with and without lung cancer were compared and there was only a significant difference in mortality [n %, 3 (15.8), 38 (2.5), p = 0.01)].

Univariate and multiple logistic regression analyses were performed in order to define the risk factors of mortality. In univariate analysis, COPD, ILD, and lung cancer were observed as associated with higher mortality as COPD, ILD and lung cancer OR were [OR 2.66 CI95% (Min–Max, 1.094–6.511) p = 0.02], [OR 8.54 CI 95% (Min–Max, 1.786–40.842) p = 0.03], [OR 7.36 CI95% (Min–Max, 2.058–26.332) p = 0.001] respectively. Also, advanced age, male gender and presence of chronic lung disease were found to be significantly associated with mortality in multiple logistic regression analysis (p = 0.001). It was determined that patients with chronic lung disease had 25.76-fold increased risk of mortality [OR 25.76 CI 95% (Min–Max, 2.445–271.465) p = 0.007] (Figure 2).

Discussion

Upon the evaluation of the patients who applied to our pandemic clinic, it was observed in our study that patients with concomitant chronic lung disease had a poor prognosis than those without. It was shown that early hospitalization was higher in chronic lung disease patients those without lung disease.

While the rate of hospitalization during COVID pandemic was 4.6 per 100,000, this rate was 13.8% in cases over 65 years of age. This rate was 12% (n = 178) in adults as of March 30. Comorbidities were found in 89.3% of these cases. The most common comorbidities were HT with 49.7%, obesity with 48.3%, DM with 28.3% and chronic lung diseases with 34.6%. In light of these findings, multiple comorbidities were among the most important factors in hospitalization in adults (5, 6). In our study, the most common comorbidities accompanying patients with chronic lung disease were hypertension n = 113 (48.9%), while the second and third ones were diabetes mellitus n = 61 (26.4%) and coronary artery disease n = 56 (24.2%).

In addition to chronic systemic diseases, accompanying cases of asthma, COPD and emphysema were seen most frequently among chronic lung diseases (7, 8).

In the series in which 74,439 cases were evaluated, the presence of chronic lung diseases was observed in n = 656 (9.2%) cases (2). In these series, asthma and COPD cases were evaluated in this group. It was shown that 15% of these cases were followed up in the service and 21% in intensive care (2). According to Centers for Disease Control and
Prevention (CDC) data of 2018 in the United States, asthma was 7.9% (9) in adults and COPD was 5.9% (10). COVID-19–associated hospitalization rates for patients admitted during March 2020 in US were as follows: Among 1.482 patients hospitalized with COVID-19, patients with Asthma were 17% and patients with COPD were 10.7% (10). Of the 1549 cases in our study, 231 cases (14.91%) had chronic lung disease. Of these, 120 (51.9%) patients had asthma, 97 (42%) had COPD, 11 (4.8%) had ILD, and 19 (8.2%) patients had lung cancer.

Recent meta-analyses have demonstrated an almost six times increase in the odds of mortality for patients with COPD and a 2.5 times one for those with diabetes, possibly due to the underlying pulmonary and immune dysfunction (7, 11–13). In our study, 2.66, 8.54, and 7.36 higher mortality risks were found in patients with COPD, ILD and lung cancer, respectively. However, there was no increase in mortality risk in asthmatic patients.

Also, in another analysis evaluating COVID-19 and comorbidities, chronic respiratory diseases were found to be 1.8%. When severe and mild cases of pneumonia were compared, it was shown that accompanying diseases were seen 2.46 times more in severe cases (OR 2.46; 95% CI; 1.76–3.44). In general, it has been shown that patients with severe course were older and had more comorbidities (7). In a study with influenza, the relationship between the severity of disease and comorbidities was investigated. Accordingly, it was found that cases with severe Pneumonia with COPD were at 1.49 times (OR 1.49, 95% CI: 1.10–2.01) higher mortality risk than mild cases (7, 13). In our study, cases with COPD were significantly higher in patients with critical disease than those without ($p = 0.001$).

The presence of respiratory disease has been shown to have a similar effect in patients with MERS (14). In our study, in cases with COVID-19 pneumonia, the presence of chronic lung disease, advanced age and male gender were found to be significantly associated with mortality.

In a review published on this subject, COVID-19, which is considered to have fibrotic ILD, involves the risk of transmission in the diagnostic process, and the necessary tests such as respiratory function test and bronchoscopic biopsy should be evaluated. It has been reported that they should be performed if there is an absolute indication in terms of diagnosis (2, 3). In addition, if a treatment decision that will affect the course of the disease is required in a patient monitored for COVID-19, it is recommended to perform procedures such as invasive bronchoscopic biopsy.

It was hypothesized that severe COVID-19 infection could lead to an exaggerated immune response. It remains unknown if the physician used initiation or maintenance of immunomodulatory therapies for patients with fibrotic ILD during COVID-19 Pneumonia. Also, there is no evidence that anti-fibrotic therapies impact the risk or severity of
COVID-19 infection (15–21). In our study, a significant difference was noted in terms of mortality between patients with and without ILD.

Pulmonary Embolism is reported in COVID-19 cases. Moreover, in postmortem biopsies, the presence of microthrombus in small pulmonary vessels in the lung and occlusion of the pulmonary vessels have been shown (22, 23). In our study, pulmonary embolism was detected in 6 cases and one was given thrombolytic therapy.

In the COVID-19 pandemic, cancer patients are regarded as a highly vulnerable group. Active cancer cases have more serious risks because they are immunosuppressed due to the chemotherapy and radiotherapy they receive as treatment. Therefore, if they have COVID-19 pneumonia, the treatment protocol they receive should be postponed (24). The clinical characteristics of COVID-19 infected cancer patients remain largely unknown. Anemia and hypoproteinemia were considered to be major consequences of nutritional deterioration in cancer patients according to several studies (25). In the general COVID-19 infected population, 4.7% of confirmed patients reached a clinically critical status, and 2.3% of critical cases ending in fatality (3). Early case series from US, China and Italy have suggested that patients with malignancy are more susceptible to severe infection and mortality from COVID-19 (26–29). In a national analysis of China with 1590 cases, it was found that the presence of malignancy exacerbates the course of COVID-19 3.5 times (5).

Among the malignancies within the US population there was 55% mortality among lung, 14% among breast, 20% among prostate, and 38% among colorectal cancer patients in a large-scale case study (30). The data in this study showed that comorbid diseases accompanying cancer and COVID diagnoses were significantly higher in patients who died due to chronic lung diseases, congestive heart failure and coronary artery diseases than those living. It was observed that the

### TABLE 1 Demographic parameter of patients with chronic disease (Group 1) and without chronic lung disease (Group 2).

| Variables                             | COVID-19 and lung disease (n = 231) (14.91%) | COVID-19 and without lung disease (n = 1318) (85.19%) | p       |
|---------------------------------------|---------------------------------------------|------------------------------------------------------|---------|
| Age (Mean ± SD)                       | 60.85 ± 15.28                               | 49.28 ± 17.59                                       | <0.001  |
| Male (n, %)                           | 122 (52.8)                                  | 819 (62.1)                                          | 0.007   |
| Symptoms (n, %)                       |                                             |                                                      |         |
| Dyspnea                               | 148 (64.1)                                  | 366 (27.8)                                          | <0.001  |
| Throat pain                           | 26 (11.3)                                   | 197 (14.9)                                          | 0.140   |
| Runy nose                             | 2 (0.9)                                     | 39 (3)                                               | 0.068   |
| Nausea and vomiting                   | 14 (6.1)                                    | 81 (6.1)                                             | 0.960   |
| Diarrhea                              | 6 (2.6)                                     | 79 (6)                                               | 0.037   |
| Fever                                 | 76 (32.9)                                   | 488 (37)                                            | 0.229   |
| Cough                                 | 129 (55.8)                                  | 702 (53.3)                                          | 0.468   |
| Sputum                                | 23 (10)                                     | 88 (6.7)                                             | 0.075   |
| Comorbidity (n, %)                    |                                             |                                                      |         |
| Diabetes mellitus                     | 61 (26.4)                                   | 187 (14.2)                                          | <0.001  |
| Coronary artery dis.                  | 56 (24.2)                                   | 137 (10.4)                                          | <0.001  |
| Hypertension                          | 113 (48.9)                                  | 419 (31.8)                                          | <0.001  |
| Kidney dis.                           | 16 (6.9)                                    | 56 (4.2)                                            | 0.075   |
| Others                                | 22 (9.6)                                    | 85 (6.5)                                            | 0.371   |
| Chronic lung disease (n, %)           |                                             |                                                      |         |
| Asthma                                | 120 (51.9)                                  | 0 (0)                                                | <0.001  |
| COPD                                  | 97 (42)                                     | 0 (0)                                                | <0.001  |
| Interstitial lung dis.                | 11 (4.8)                                    | 0 (0)                                                | <0.001  |
| Lung cancer                           | 19 (8.2)                                    | 0 (0)                                                | <0.001  |
| Physical examination                  |                                             |                                                      |         |
| sO2 (Mean ± SD)                       | 91.56 ± 5.51                                | 93.70 ± 3.63                                        | <0.001  |
| Respiratory rate (Mean ± SD)          | 21.27 ± 4.08                                | 20.37 ± 2.82                                        | 0.001   |
| Blood pressure _ Systolic (Mean ± SD [Median (min-max)]) | 93.19 ± 24.88 [90 (24–140)] | 90.48 ± 21.41 [90 (24–140)] | 0.116   |
| Blood pressure _ Diastolic (Mean ± SD [Median (min-max)]) | 64.38 ± 10.58 [60 (59–90)] | 62.66 ± 8.40 [60 (59–90)] | 0.032   |
| qSOFA scores (Mean ± SD [Median (min-max)]) | 0.41 ± 0.70 [0 (0–3)] | 0.33 ± 0.59 [0 (0–3)] | 0.162   |
TABLE 2  The severity of pneumonia follow-up parameter of patients with chronic disease (Group 1) and without chronic lung disease (Group 2).

| Variables                                      | COVID-19 and lung disease (n = 231) (14.91%) | COVID-19 and without lung disease (n = 1318) (85.19%) | P    |
|------------------------------------------------|---------------------------------------------|--------------------------------------------------------|------|
| **Severity of pneumonia (n, %)**               |                                             |                                                        |      |
| Severe pneumonia (SARI)                         | 11 (4.8)                                   | 83 (6.3)                                               | 0.001|
| Mild disease                                   | 65 (28.1)                                  | 344 (26.1)                                             |      |
| Critical illness                               | 17 (7.4)                                   | 34 (2.6)                                               |      |
| Pneumonia                                      | 138 (59.7)                                 | 857 (65)                                               |      |
| **Treatment (n, %)**                           |                                             |                                                        |      |
| Oseltamivir                                    | 117 (50.6)                                 | 456 (34.6)                                             | <0.001|
| Enoxoparine (Subcutan)                         | 170 (73.6)                                 | 704 (53.4)                                             | <0.001|
| Antibiotic                                     | 185 (80.1)                                 | 798 (60.5)                                             | <0.001|
| Intensive care unit follow-up [Mean ± SD [Median (min-max)]] | 8.92 ± 7.28 [7 (1–27)] | 8.92 ± 7.22 [7 (1–30)] | 0.843|
| Intensive care needs developed in the day of hospitalization [Mean ± SD [Median (min-max)]] | 2.60 ± 2.04 [1.5 (1–7)] | 3.78 ± 8.90 [2 (1–90)] | 0.651|
| Mechanic ventilation on the day of hospitalization? [Mean ± SD [Median (min-max)]] | 3.27 ± 3.88 [1 (1–12)] | 3.88 ± 2.75 [3 (1–10)] | 0.270|
| Oxygen (n, %)                                   | 95 (41.1)                                  | 260 (19.7)                                             | <0.001|
| High flow oxygen (n, %)                        | 4 (1.7)                                    | 28 (2.1)                                               | 1.000|
| NIMV* (n, %)                                   | 3 (1.3)                                    | 5 (0.4)                                                | 0.103|
| Mechanic ventilation (n, %)                    | 11 (4.8)                                   | 31 (2.4)                                               | 0.038|
| Mechanic ventilation duration [Mean ± SD [Median (min-max)]] | 14.67 ± 11.22 [15 (3–27)] | 14.68 ± 7.67 [15 (2–27)] | 0.975|
| ECMO* (n, %)                                   | 1 (0.4)                                    | 0 (0)                                                  | 0.149|
| Mortality (n, %)                               | 12 (5.2)                                   | 29 (2.2)                                               | 0.009|

NIMV, non-invasive mechanic ventilation; ECMO, extracorporeal membrane oxygenation.

TABLE 3  The laboratory follow-up parameter of patients with chronic disease (Group 1) and without chronic lung disease (Group 2).

| Variables                                      | COVID-19 and lung disease (n = 231) (14.91%) | COVID-19 and without lung disease (n = 1318) (85.19%) | P    |
|------------------------------------------------|---------------------------------------------|--------------------------------------------------------|------|
| WBC* x10^9/L (1–3 Day)                         | 7310 (1520–44000)                          | 7000 (1141–59290)                                       | <0.001|
| Lymphocytes 10^9/L (1–3 Day)                   | 1200 (0–33060)                             | 1435 (0–49620)                                         | 0.017|
| Hgb* g/dl (1–3 ay)                             | 13.40 (6–19)                               | 13.70 (6–19)                                           | 0.025|
| PLT* g/dl (1–3 Day)                            | 231000 (77000–560000)                      | 232000 (61000–607000)                                   | 0.514|
| Urea mg/dL (1–3 Day)                           | 2.5 (0–1394)                               | 2.5 (0–43953)                                          | 0.106|
| Crea mg/dL (1–3 Day)                           | 0.83 (0–7)                                 | 0.83 (0–10)                                            | 0.550|
| AST* U/L (1–3 Day)                             | 21 (4–131)                                 | 22 (2–1015)                                            | 0.041|
| ALT* U/L (1–3 Day)                             | 20 (6–147)                                 | 26 (3–634)                                             | <0.001|
| CK* U/L (1–3 Day)                              | 79 (2–1229)                                | 90 (1–6197)                                            | 0.012|
| LDH* U/L (1–3 Day)                             | 244 (132–1051)                             | 225 (38–2586)                                          | <0.001|
| CRP* μg/L (1–3 Day)                            | 0.04 (0–262)                               | 0.02 (0–506)                                           | 0.004|
| PCT* μg/L (1–3 Day)                            | 0.05 (0–48)                                | 0.04 (0–142)                                           | 0.004|
| Myoglobin ng/L (1–3 Day)                       | 66 (8–1000)                                | 46 (0–1000)                                            | <0.001|
| Ferritin μ g/L (1–3 Day)                       | 85.5 (1–15441)                             | 108 (1–9569)                                           | 0.005|
| D-Dimer mg/L (1–3 Day)                         | 0.74 (0–35)                                | 0.50 (0–44)                                            | <0.001|
| Fibrinogen ng/L (1–3 Day)                      | 4.01 (2–43)                                | 3.53 (0–92)                                            | 0.001|
| IL-6 pg/mL (1–3 Day)                           | 11.60 (2–4399)                             | 8.96 (1–4405)                                          | 0.180|

*Cells represent median (min-max).

WBC, white blood cell; Hgb, hemoglobin; PLT, platelet; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase; LDH, lactic dehydrogenase; CRP, C-reactive protein; PCT, procalcitonin; IL-6, Interleukin-6.
mortality rate increased in cases with malignancy compared to those without.

Prone position and high-flow oxygen therapy were applied in cases whose hypoxia continued despite high-dose nasal oxygen therapy while following up the cases with COVID-pneumonia. In the literature, the benefit of high-flow oxygen therapy in COVID-19 pneumonia is discussed in studies comparing both treatments (31).

In our study, it was reported that the comorbidity of asthma and bronchiectasis in cases with COVID did not adversely affect the prognosis. In the literature, it has been reported in previous publications that asthma and bronchiectasis are worse prognostic factors (32–34). However, in our study, it was not possible to obtain the severity of the asthmatic cases from the file information and whether bronchiectasis was accompanied in the same case. In addition, it is not clear whether the main factor contributing to the clinical severity of the patient is related to the pathogenesis of COVID-19 or to the severity of concomitant bronchiectasis or asthma.

Our study has some restrictive points as cases of asthma, COPD, and bronchiectasis diagnoses were based on file and hospital follow-up. Evidence-based tests such as respiratory function tests and allergic skin tests required for diagnosis were currently not available due to pandemic conditions. Diagnoses based on clinical, laboratory and radiological data and records in the hospital data system were analyzed. According to the pandemic guidelines, tests such as respiratory function tests and allergic skin tests could not be updated. Although mortality was higher with COPD, ILD and lung cancer in our study, there is a need to confirm these results with larger cohort studies on this subject.

**Conclusion**

The presence of chronic lung disease, advanced age and male gender was found to be significantly associated with mortality in our study. In chronic lung diseases, the mortality rate of cases with COPD, lung cancer and ILD was found to be significantly higher than those without. This is the first study investigating the relationship between chronic lung diseases and pneumonia severity and mortality. However prospective cohort studies evaluating the relationship between chronic lung disease and COVID-19 Pneumonia should be conducted in the future.

**Data availability statement**

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**Ethics statement**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the patients/participants or patients/participants legal guardian/next of kin was not required to participate in this
study in accordance with the national legislation and the institutional requirements.

Author contributions

HK, EA, AgK, AS, and EU: conceptualization. HK, EA, AgK, and EU: methodology. DG and SH: software, validation, and formal analysis. HK, EA, AgK, EU, RG, BK, IA, MC, EhA, EP, FS, YK, SG, EM, ME, AD, HE, ZH, AK, FE, AA, EgA, SK, EG, EK, OI, AY, BC, EG, IT, DG, SH, and AS: investigation and resources. HK, EA, AgK, EU, RG, BK, IA, MC, EhA, EP, FS, YK, SG, EM, ME, AD, HE, and ZH: data curation. HK, EA, and AgK: writing. HK, EA, AgK, and AS: visualization. AgK and AS: supervision. HK: project administration. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. R.T. Ministry of Health Directorate for Public Health. COVID-19(SARS-CoV2 Infection) Guide. Ankara: R.T. Ministry of Health Directorate for Public Health (2020).

2. Centers for Disease Control [CDC] Covid-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:388–6. doi: 10.15585/mmwr.mm6913e2

3. Wong AW, Fidler L, Marcoux V, Johannson KA, Assayad Y, Fisher JH, et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic. Chest. (2020) 158:1069–78. doi: 10.1016/j.chest.2020.04.019

4. CDC. Coronavirus 2019 (COVID-19) Cases in U.S. Atlanta, GA: CDC (2020).

5. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-19, United States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:458–64. doi: 10.15585/mmwr.mm6915e3

6. Guan WJ, Liang WH, Zhao Y, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. (2020) 55:2000547. doi: 10.1183/13993003.00547–2020

7. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. (2020) 94:91–5. doi: 10.1016/j.ijid.2020.03.017

8. CDC. Human Infection With 2019 Novel Coronavirus Under Investigation (PUI) and Case Report Form. Atlanta, GA: CDC (2020).

9. National Health Interview Survey. Early Release of Selected Estimates Based on Data From the 2018 National Health Interview Survey. Atlanta, GA: CDC (2020).

10. Croft JB, Wheaton AG, Liu Y, Xu F, Lu H, Matthews KA, et al. Urban-rural county and state differences in chronic obstructive pulmonary disease—United States, 2015. MMWR Morb Mortal Wkly Rep. (2018) 67:205–11. doi: 10.15585/mmwr.mm6707a1

11. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. (2020) 8:12. doi: 10.18632/aging.100300

12. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. (2020) 12:8.

13. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and metaanalysis. BMJ. (2013) 347:f5061. doi: 10.1136/bmj.f5061

14. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. (2016) 49:129–33. doi: 10.1016/j.ijid.2016.06.015

15. Kaltiös A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immune compromised host. Curr Opin Infect Dis. (2012) 25:423–30. doi: 10.1097/QCO.0b013e328356606b

16. D’Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. (2020) 26:832–4. doi: 10.1002/lt.25756

17. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. (2004) 31:384–9. doi: 10.1016/j.jcv.2004.07.006

18. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. (2003) 349:507–8. doi: 10.1056/NEJM200307313490319

19. Hui DSC, Zuhla D. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. (2019) 33:869–89. doi: 10.1016/j.idc.2019.07.001

20. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-8

21. Zuhla D, Hui DSC, Azhar EI, Memish ZA, Meurier M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. (2020) 395:e35–6. doi: 10.1016/S0140-6736(20)30305-6

22. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094–9. doi: 10.1111/jth.14817

23. Rouzbehzadeh MR, Haseiri S. Diagnosing pulmonary thromboembolism in COVID19: a stepwise clinical and imaging approach. Acad Radiol. (2020) 27:896–7. doi: 10.1016/j.acra.2020.04.023

24. Kumar S, Chmura S, Robinson C, Lin SH, Gadgeel SM, Donington J, et al. Alternative multidisciplinary management options for locally advanced non-small cell lung cancer during the COVID-19 global pandemic. J Thorac Oncol. (2020) 15:1137–46. doi: 10.1016/j.jtho.2020.04.016

25. Zhang YF, Zhu YF, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. (2020) 31:894–901. doi: 10.1016/j.annonc.2020.03.296

26. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. (2020) 21:335–7. doi: 10.1016/S1470-2045(20)30096-6
27. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. *Lancet Oncol.* (2020) 21:e180. doi: 10.1016/S1470-2045(20)30150-9

28. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. *Lancet Oncol.* (2020) 21:e181. doi: 10.1016/S1470-2045(20)30149-2

29. Onder G, Rezza G, Brusarosco S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA.* (2020) 323:1775–6. doi: 10.1001/jama.2020.4683

30. Mehta V, Goel S, Rafi KR, Cole D, Goldfinger M, Villaorduna AA, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. *Cancer Discov.* (2020) 10:935–41. doi: 10.1158/2159-8290.CD-20-break0516

31. Crimi C, Noto A, Madotto F, Ippolito M, Nolasco S, Campisi R, et al. High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomized controlled trial. *Thorax.* (2022) 1–8. doi: 10.1136/thoraxjnl-2022-218806

32. Crimi C, Ferri S, Campisi R, Crimi N. The link between asthma and bronchiectasis: state of the art. *Respiration.* (2020) 99:465–76. doi: 10.1159/000507228

33. Ferri S, Crimi C, Campisi R, Cacopardo G, Paoletti G, Puggioni E, et al. Impact of asthma on bronchiectasis severity and risk of exacerbations. *J Asthma.* (2022) 59:469–75. doi: 10.1080/02770903.2020.1857395

34. Ferri S, Crimi C, Heffler E, Campisi R, Noto A, Crimi N. Vitamin D and disease severity in bronchiectasis. *Respir Med.* (2019) 148:1–5. doi: 10.1016/j.rmed.2019.01.009